Author:
Augustovski Federico,Bardach Ariel,Santoro Adrián,Rodriguez-Cairoli Federico,López-Osornio Alejandro,Argento Fernando,Havela Maissa,Blumenfeld Alejandro,Ballivian Jamile,Solioz Germán,Capula Analía,López Analía,Cejas Cintia,Savedoff William,Palacios Alfredo,Rubinstein Adolfo,Pichon-Riviere Andrés
Abstract
Abstract
Objective
Our study analyzes the cost-effectiveness of the COVID-19 vaccination campaigns in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru.
Methods
Using a previously published SVEIR model, we analyzed the impact of a vaccination campaign (2021) from a national healthcare perspective. The primary outcomes were quality adjusted life years (QALYs) lost and total costs. Other outcomes included COVID-19 cases, hospitalizations, deaths, and life years. We applied a discount rate of 3% for health outcomes. We modeled a realistic vaccination campaign in each country (the realistic country-specific campaign). Additionally, we assessed a standard campaign (similar, “typical“ for all countries), and an optimized campaign (similar in all countries with higher but plausible population coverage). One-way deterministic sensitivity analyses were performed.
Findings
Vaccination was health improving as well as cost-saving in almost all countries and scenarios. Our analysis shows that vaccination in this group of countries prevented 573,141 deaths (508,826 standard; 685,442 optimized) and gained 5.07 million QALYs (4.53 standard; 6.03 optimized). Despite the incremental costs of vaccination campaigns, they had a total net cost saving to the health system of US$16.29 billion (US$16.47 standard; US$18.58 optimized). The realistic (base case) vaccination campaign in Chile was the only scenario, which was not cost saving, but it was still highly cost-effective with an ICER of US$22 per QALY gained. Main findings were robust in the sensitivity analyses.
Interpretation
The COVID-19 vaccination campaign in seven Latin American and Caribbean countries -that comprise nearly 80% of the region- was beneficial for population health and was also cost-saving or highly cost-effective.
Funder
Inter-American Development Bank
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
2. COVID-19 Data Explorer. Our World in Data. https://ourworldindata.org/explorers/coronavirus-data-explorer. Accessed March 21, 2022.
3. Redirect Notice. https://www.google.com/url?q=https://ourworldindata.org/explorers/coronavirus-data-explorer&sa=D&source=docs&ust=1647349603934767&usg=AOvVaw1zBxFfEVULBAK_7szYbwUZ. accessed March 15, 2022.
4. Siedner MJ, Alba C, Fitzmaurice KP, et al. Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries. 2021; published online May 2. https://doi.org/10.1101/2021.04.28.21256237.
5. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39:1157–64.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献